


Cancer

Antibodies for Cancer Research



biocell.com

BioCell

Antibodies for Cancer Research



Antigen	Reactivity	Application	Clone	Catalog Number	Isotype Control
4-1BB (CD137)	mouse	<i>in vivo</i> activation of 4-1BB	LOB12.3	BP0169	BP0088
4-1BB (CD137)	mouse	<i>in vivo</i> 4-1BB stimulation, <i>in vitro</i> 4-1BB stimulation	3H3	BE0239	BE0089
4-1BB (CD137)	mouse	<i>in vitro</i> 4-1BB blockade, FC	17B5	BE0296	BE0087
4-1BBL (CD137L)	mouse	<i>in vivo</i> 4-1BBL blockade, , ELISA	TKS-1	BE0110	BE0089
B7-1 (CD80)	mouse	<i>in vivo</i> CD80 blockade, Affinity chromatography	1G10	BE0134	BE0089
BTLA (CD272)	mouse	<i>in vivo</i> BTLA stimulation, <i>in vivo</i> BTLA blockade	6A6	BE0132	BE0091
BTLA (CD272)	mouse	<i>in vivo</i> stimulation of BTLA, <i>in vitro</i> stimulation of BTLA, FC	PK18.6	BE0153	BE0088
BTLA (CD272)	mouse	<i>in vivo</i> BTLA blockade, <i>in vitro</i> T cell stimulation/activation, FC	PJ196	BE0196	BE0083
CD19	mouse	<i>in vivo</i> B cell depletion, <i>in vivo</i> CD19 neutralization, <i>in vitro</i> B cell negative selection, FC	1D3	BE0150	BE0089
CD19	human	FC, Functional assays, IF, Chimeric antigen receptor construction	4G7	BE0281	BE0083
CD20	human/monkey	<i>in vivo</i> B cell depletion in hCD20 Tg mice, IHC-F, IP, FC	2H7	BE0276	BE0086
CD20	mouse	FC, WB, Not recommended for <i>in vivo</i> B cell depletion	AISB12	BE0302	BE0089
CD20	mouse	<i>in vivo</i> B cell depletion, WB	MB20-11	BE0356	BE0366
CD28	mouse	<i>in vitro</i> T cell stimulation/activation, <i>in vivo</i> CD28 blockade	37.51	BE0015-1	BE0087
CD28	mouse	<i>in vitro</i> T cell stimulation/activation	PV-1	BE0015-5	BE0091
CD28	human	<i>in vitro</i> T cell stimulation/activation	9.3	BE0248	BE0085
CD28	human/monkey	<i>in vitro</i> T cell stimulation/activation, IP, FC, IHC-F	CD28.2	BE0291	BE0083
CD28	mouse	<i>in vivo</i> T cell stimulation/activation, <i>in vitro</i> T cell stimulation/activation	D665	BE0328	BE0083
CD38	mouse	<i>in vivo</i> CD38 stimulation, <i>in vitro</i> CD38 stimulation, <i>in vitro</i> B cell activation, IF, ELISA, FC	NIMR5	BE0317	BE0089
CD40	mouse	<i>in vivo</i> CD40 activation, <i>in vitro</i> B cell stimulation/activation	FGK4.5/FGK45	BP0016-2	BP0089
CD40L (CD154)	mouse	<i>in vivo</i> blocking of CD40/CD40L signaling, <i>in vitro</i> blocking of CD40/CD40L signaling, WB	MR-1	BP0017-1	BP0091
CD40L (CD154)	human/monkey	<i>in vitro</i> blocking of CD40/CD40L signaling, <i>in vivo</i> blocking of CD40/CD40L signaling, IP, FC	5C8	BE0292	BE0085
CD44	mouse/human	<i>in vivo</i> CD44 neutralization, , <i>in vitro</i> CD44 neutralization	IM7	BE0039	BE0090
CD44	human	<i>in vivo</i> CD44 blockade in xenografts, <i>in vitro</i> CD44 blockade, WB, IF	Hermes-1	BE0262	BE0089
CD47	human	<i>in vitro</i> CD47 neutralization, <i>in vivo</i> CD47 neutralization in human tumor xenograft models or humanized mice, FC	B6.H12	BE0019-1	BE0083
CD47	human/mouse/rat	<i>in vivo</i> CD47 blockade, <i>in vitro</i> CD47 blocking, IF	MIAP410	BP0283	BE0083
CD47 (IAP)	mouse	<i>in vivo</i> CD47 blockade, <i>in vitro</i> CD47 blockade, IF	MIAP301	BE0270	BE0089
CD69	mouse	<i>in vivo</i> down-regulation of CD69 expression, Functional assays	CD69.2.2	BE0330	BE0083
CD70	mouse	<i>in vivo</i> CD70 blockade, <i>in vitro</i> CD70 blockade, FC	FR70	BE0022	BE0090
CD71 (TfR1)	mouse	<i>in vivo</i> depletion of CD71+ cells	R17 217.1.3	BE0175	BE0089
CD71 (TfR1)	mouse	<i>in vivo</i> depletion of CD71+ cells, IF, IHC-F, WB	8D3	BE0329	BE0089
CD71 (TfR1)	rat/mouse	Targeted drug delivery to the brain, IHC-F, FC	OX-26	BE0331	BE0085
CD73	mouse	<i>in vivo</i> CD73 blockade, , <i>in vitro</i> CD73 blockade	TY/23	BE0209	BE0089
CD80 (B7-1)	mouse	<i>in vivo</i> CD80 blockade, FC	16-10A1	BE0024	BE0091
CD86 (B7-2)	mouse	<i>in vivo</i> CD86 blockade, FC	GL-1	BE0025	BE0089
CD96	mouse	<i>in vivo</i> CD96 blocking, <i>in vitro</i> CD96 blocking, FC	3.3	BE0337	BE0088
CD103	mouse	<i>in vivo</i> CD103 neutralization, IF, FC	M290	BE0026	BE0089
CD172a (SIRPa)	mouse	<i>in vivo</i> SIRPa blocking, <i>in vitro</i> SIRPa blocking, WB, IP, FC	P84	BE0322	BE0088
CD209b (SIGN-R1)	mouse	<i>in vivo</i> SIGN-R1 blockade, IHC-F, WB, FC	22D1	BE0220	BE0091
CD276 (B7-H3)	mouse	<i>in vivo</i> B7-H3 blockade, FC	MJ18	BE0124	BE0088
CD314 (NKG2D)	mouse	<i>in vivo</i> NKG2D blockade, <i>in vitro</i> NKG2D blockade, FC	CX5	BE0334	BE0088
CD326 (EpCAM)	mouse	IHC-F, IF, FC, WB	G8.8	BE0346	BE0089
CD326 (EpCAM)	human	IHC-P, IF, FC, IP	Ber-EP4	BE0386	BE0083
c-Kit (CD117)	mouse	FC, IF, IHC	2B8	BE0280	BE0090
c-Kit (CD117)	mouse	<i>in vivo</i> mast cell depletion, <i>in vivo</i> c-Kit+ cell depletion, <i>in vitro</i> c-Kit neutralization, IP, FC	ACK2	BE0293	BE0090
c-myc	human	WB, ELISA, IP, FC	9E10	BE0238	BE0083
CLEC9A (CD370)	mouse	<i>in vivo</i> CLEC9A blockade, <i>in vivo</i> Ag targeting to CLEC9A+ DCs, WB, ELISA, IP, IF, FC	7H11	BE0305	BE0088
CSF1R (CD115)	mouse	<i>in vivo</i> macrophage depletion, <i>in vitro</i> CSF1R neutralization, <i>in vivo</i> monocyte depletion, FC, WB	AFS98	BP0213	BP0089
CSF1R (CD115)	human	<i>in vitro</i> CSF1R neutralization, IHC-P, Functional assays, FC	2-4A5-4	BE0347	BE0088
CTLA-4 (CD152)	mouse	<i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, FC, WB	UC10-4F10-11	BP0032	BP0091



	InVivoMab vs. InVivoPlus	
	InVivoMab	InVivoPlus
purity level	> 95%	> 95%
protein aggregates validated at ≤ 5%		
azide and carrier protein free		
endotoxin concentration	< 2EU/mg	< 1EU/mg
validated by immunoblot, FC, or ELISA		
screened for murine pathogens		
available in bulk quantities		

Antigen	Reactivity	Application	Clone	Catalog Number	Isotype Control
CTLA-4 (CD152)	mouse	<i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, WB	9H10	BP0131	BP0087
CTLA-4 (CD152)	mouse	<i>in vivo</i> CTLA-4 neutralization, WB	9D9	BP0164	BP0086
CTLA-4 (CD152)	human	<i>in vitro</i> CTLA-4 neutralization, FC	BN13	BE0190	BE0085
DR5 (CD262)	mouse	<i>in vivo</i> induction TRAIL-mediated apoptosis, <i>in vitro</i> induction TRAIL-mediated apoptosis	MD5-1	BE0161	BE0091
EGFR	human	<i>in vitro</i> EGFR blockade, <i>in vivo</i> EGFR blockade in xenografts, WB, Functional assays	225 (HB8508)	BE0278	BE0083
EGFR	human	<i>in vitro</i> EGFR blockade, <i>in vivo</i> EGFR blockade in xenografts, WB, Functional assays, IP, IHC-P, IF, FC	528	BE0279	BE0085
EphA2	human	IHC-P, IP, Functional assay	B2D6	BE0341	BE0086
E-Cadherin (CD324)	mouse	<i>in vivo</i> E-Cadherin neutralization, <i>In vitro</i> E-Cadherin neutralization, IF, IP, WB	DECMA-1	BE0352	BE0088
E-selectin (CD62E)	mouse	<i>in vivo</i> E-selectin blockade, <i>in vitro</i> E-selectin blockade, IHC-F	9A9	BE0294	BE0090
FasL (CD178)	mouse	<i>in vivo</i> FasL blockade, <i>In vitro</i> FasL blockade, Functional assay, IHC-P, FC	MFL3	BE0319	BE0091
FGL-1	mouse	<i>in vivo</i> FGL-1 blockade, <i>in vitro</i> FGL-1 blockade, FC, IHC-P	177R4	BE0332	BE0089
Galectin-9	mouse	<i>in vivo</i> Galectin-9 blockade, <i>in vitro</i> Galectin-9 blockade	RG9-1	BE0218	BE0090
GITR	mouse	<i>in vivo</i> GITR stimulation	DTA-1	BE0063	BE0090
GM-CSF	mouse	<i>in vivo</i> GM-CSF neutralization, <i>in vitro</i> GM-CSF neutralization, FC	MP1-22E9	BE0259	BE0089
HER2 (neu)	human/rat	<i>in vivo</i> HER2/neu inhibition, <i>in vitro</i> HER2/neu inhibition, IP, IF, FC	7.16.4	BE0277	BE0085
ICOS	mouse	<i>in vivo</i> blocking of ICOS/ICOSL signaling, FC	7E.17G9	BE0059	BE0090
ICOSL (CD275)	mouse	<i>in vivo</i> ICOSL neutralization	HK5.3	BE0028	BE0089
IL-17F	mouse	<i>in vivo</i> IL-17F neutralization	MM17F8F5.1A9	BE0303	BE0083
IL-27 p28	mouse	<i>in vivo</i> IL-27 p28 neutralization, <i>in vitro</i> IL-27 p28 neutralization, FC	MM27.7B1	BE0326	BE0085
IL-7Ra (CD127)	mouse	<i>in vivo</i> blocking of IL-7Ra signaling, FC	A7R34	BE0065	BE0089
Jagged2	mouse	<i>in vivo</i> Jagged 2 neutralization	HMJ2-1	BE0125	BE0091
LAG-3	mouse	<i>in vivo</i> LAG-3 neutralization, <i>in vitro</i> LAG-3 neutralization, FC, WB	C9B7W	BP0174	BP0088
LPAM-1 (Integrin α4β7)	mouse	<i>in vivo</i> Integrin α4β7 neutralization, FC	DATK32	BE0034	BE0089
LRP1 (CD91)	mouse/human/rat	WB, IF, IP	11H4	BE0333	BE0083
Ly6G	mouse	<i>in vivo</i> neutrophil depletion, <i>in vivo</i> MDSC depletion, IF, IHC-P, IHC-F, FC	1A8	BP0075-1	BP0089
Ly6G/Ly6C (Gr-1)	mouse	<i>in vivo</i> neutrophil depletion, IHC-P, IHC-F, IF, FC	NIMP-R14	BE0320	BE0090
Ly6G/Ly6C (Gr-1)	mouse	<i>in vivo</i> depletion of Gr-1+ myeloid cells, FC, IHC-P, IHC-F	RB6-8C5	BP0075	BP0090
MAGEC2 (CT10)	human	IHC-P, IF, WB	LX-CT10.5	BE0335	BE0085
MDR-1(CD243)	human/monkey	<i>in vivo</i> MDR-1 blocking/depletion in xenogeneic murine tumor models, <i>in vitro</i> MDR-1 blocking, IHC-P	UIC2	BE0340	BE0085
MUC1 (CD227)	human	<i>in vivo</i> administration in mouse xenograft models, IHC-P, IF, <i>in vitro</i> cell cytotoxicity assay, WB	C595 (NCRC48)	BE0336	BE0093
NKG2A/C/E	mouse	<i>in vivo</i> NKG2A blockade (see description), <i>in vitro</i> NKG2A blockade, IHC-F, FC	20D5	BE0321	BE0089
NKG2D	mouse	<i>in vivo</i> NKG2D blockade	HMG2D	BE0111	BE0091
PD-1(CD279)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, WB	J43	BP0033-2	BP0091
PD-1(CD279)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14	BP0146	BP0089
PD-1(CD279)	human	<i>in vitro</i> PD-1 neutralization, <i>in vivo</i> PD-1 blockade in humanized mice	J116	BE0188	BE0083
PD-1(CD279)	human	<i>in vivo</i> PD-1 blockade in humanized mice, FC	J110	BE0193	BE0083
PD-1(CD279)	mouse	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, IF, WB, FC	29F.1A12	BP0273	BP0089
PD-1(p248Tyr)	mouse, human	WB, FC	407.6G12	BE0387	BE0085
PD-L1	mouse	<i>in vivo</i> and <i>in vitro</i> blocking of PD-L1/CD80 (B7-1) interactions, ELISA, FC	10F.2H11	BE0361	BE0090
PD-L1(B7-H1)	mouse	<i>in vivo</i> PD-L1 blockade, IF, IHC-F, FC, WB	10F.9G2	BP0101	BP0090
PD-L1(B7-H1)	human	<i>in vitro</i> PD-L1 blockade, Functional assays, IHC-F, FC	29E.2A3	BE0285	BE0086
PD-L2(B7-DC)	mouse	<i>in vivo</i> PD-L2 blockade, <i>in vitro</i> PD-L2 blockade, IHC-F, FC	TY25	BE0112	BE0089
RANKL (CD254)	mouse	<i>in vivo</i> RANKL blockade	IK22/5	BE0191	BE0089
TIM-1(CD365)	mouse	<i>in vivo</i> TIM-1 blockade	RMT1-10	BE0113	BE0089
TIM-1(CD365)	mouse	<i>in vivo</i> TIM-1 blockade, <i>in vitro</i> TIM-1 blockade	3D10	BE0314	BE0088
TIM-3(CD366)	mouse	<i>in vivo</i> TIM-3 neutralization, <i>in vitro</i> TIM-3 blocking, FC	RMT3-23	BP0115	BP0089
TNFα	mouse/rat/rabbit	<i>in vivo</i> TNFα neutralization, FC	TN3-19.12	BE0244	BE0091
VEGFR-2	mouse	<i>in vivo</i> blocking of VEGF/VEGFR-2 signaling, <i>in vitro</i> blocking of VEGFR signaling, WB	DC101	BP0060	BP0088
VISTA	mouse	<i>in vivo</i> blocking of VISTA signaling, <i>in vitro</i> blocking of VISTA signaling	13F3	BP0310	BP0091
VLDL-R	mouse/rat/bovine	WB	IgG-6A6	BE0345	BE0083



For over 25 years, scientists have trusted Bio X Cell as their go-to source for *in vivo* functional grade antibodies. This is reflected in over 20,000 peer-reviewed publications citing Bio X Cell products. We understand this responsibility is of paramount importance and remain committed to producing antibodies of unparalleled quality and consistency, enabling our partners around the globe to accelerate research and discoveries.

Bio X Cell
bioxcell.com

CustomerService@biocell.com | 1.866.787.3444

Conditions: For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

